WuXia^TM

WuXia^TM Cell Line Development

CHO-K1 Platform - The Ideal
Solution from cDNA to GMP Production

WuXi Biologics offers comprehensive mammalian cell line development (CLD) capabilities for various biotherapeutics. Our program typically starts with client-provided DNA or protein sequences and ends with the delivery of high-yielding, well-characterized, stable single clones. The Chinese word “WuXia” translates to “flawless or ideal” in English. Hence, this is why we chose to name our cell line development (CLD) platform “WuXia.”

Industry-leading CLD

CHO-K1

Timeline
(DNA to MCB*)

Average
Productivity

9-10 weeks

3.3 g/L (Pool)

5.6 g/L (Clone)

*Timeline to the initiation of MCB generation

The WuXia^TM CLD System Is Ideal for a Wide Variety of Biologics
WuXia^TM Platform Features

Artificial Intelligence (AI)-assisted codon optimization
Automated high-throughput systems
State-of-the-art processes for determination of monoclonality
Next Generation Sequencing (NGS)-guided clone screening
Use of commercial, off-the-shelf cell culture medium
Seamless system from candidate screening & developability studies to GMP production
Enables 2.5 to 6-month DNA to IND timeline for COVID & other pandemic diseases

Over 300 cell lines developed and 50+ submitted in Global INDs

WuXiaTM

Cell Line Development Case Studies:

WuXia^TM